What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen”In the company’s words, NCT04150497 on ClinicalTrials.gov
- Tested for
- B-cell Acute Lymphoblastic Leukemia
- Main trialPhase 1/2
- “This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to determine the optimal dose of CLLS52 as part of the FCA LD regimen followed by the Recommended Phase 2 Dose (RP2D) of UCART22 and evaluate the safety and efficacy of UCART22.”In the company’s words, NCT04150497 on ClinicalTrials.gov
Other drugs for B-cell Acute Lymphoblastic Leukemia
- TisagenlecleucelNovartis · Phase 3
- Human immunoglobulin GCSL Behring · Phase 3
- MK-1045Merck & Co. · Phase 2/3
- YK012Excyte Biopharma Ltd · Phase 1/2
- Autologous BCMA/CD19 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous BCMA/CD38 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
Coming up0
No dates coming up.
Changes2
Last 90 days- 9 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT04150497
- 9 NovCompletion date moved: 2026-06-30 to 2026-09-16 · ClinicalTrials.gov NCT04150497
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 16 Sep 2026 | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026